Holter monitor for low-risk patients gains FDA clearance
Biotricity, a California-based healthcare technology company, has received FDA clearance for its new three-lead electrocardiogram (ECG) and arrhythmia monitoring solution.
The Biotres Cardiac Monitoring Device was built to help monitor the cardiac health of low-risk patients. It includes Bluetooth connectivity, a rechargeable battery and an adjustable design that can be updated in the future as additional features are finalized.
“Cardiac disease remains a chronic issue, requiring persistent intervention, monitoring and management and we believe Biotres may provide a critical tool for improving patient lives and reducing costs,” Waqaas Al-Siddiq, PhD, Biotricity founder and CEO, said in a prepared statement.
Al-Siddiq also pointed to the company’s recent financing success, saying that Biotricity now has a great opportunity to expand its commercialization efforts.
The Biotres Cardiac Monitoring Device is scheduled to be available for purchase on April 1.